Epion Therapeutics' CMO, Michael W. Belin, MD, Shares Phase 3 Updates at Eyecelerator during ASCRS Conference

Burlington, MA – April 8, 2024 – Epion Therapeutics’ Chief Medical Officer Michael W. Belin, MD, presented Phase 3 trial updates at Eyecelerator @ ASCRS 2024 on April 4th, 2024.

During his presentation at Eyecelerator, Belin described the science behind Epion’s novel drug-device combination, EpiSmart, and updated attendees on enrollment in Epion’s Phase 3 Apricity studies. The Apricity studies focus on evaluating the efficacy and safety of EpiSmart, an investigational epithelium-on cross-linking system for keratoconus. This innovative treatment aims to strengthen corneal tissue without the need for chemical or mechanical disruption of the epithelium, potentially reducing patient discomfort and recovery time.

“Our Phase 3 clinical trials are proceeding rapidly with over 25% of patients enrolled," Dr. Belin shared. “Seeing such strong enrollment numbers in our studies demonstrates the eagerness of patients and clinicians to embrace true epithelium-on cross-linking, when approved.”

About Epion Therapeutics:

Epion is developing EpiSmart, a minimally-invasive treatment for keratoconus and ectatic corneal disease that could bring early intervention to millions of patients globally. Our approach is a transformative cross-linking system designed to treat keratoconus without chemical or mechanical disruption of the epithelium, allowing for a rapid return to normal activities.

For more information, please visit epiontx.com.